Understanding Who Makes Rozlytrek? A Comprehensive Guide
•
4 min read
Rozlytrek (entrectinib) received its initial accelerated approval from the U.S. Food and Drug Administration (FDA) in August 2019 for specific types of cancer. The answer to who makes Rozlytrek involves a complex history of development and acquisition, leading to the current manufacturer, Genentech, a member of the Roche Group.
